{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:51:46Z","timestamp":1790491906327,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.maturitas.2008.04.009","type":"journal-article","created":{"date-parts":[[2008,6,5]],"date-time":"2008-06-05T08:36:05Z","timestamp":1212654965000},"page":"92-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women"],"prefix":"10.1016","volume":"60","author":[{"given":"Wen-Ling","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Tai","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Huei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2008.04.009_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1028-4559(07)60006-0","article-title":"Standard and low-dose hormone therapy for postmenopausal women\u2014focus on the breast","volume":"46","author":"Wang","year":"2007","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/edrv.20.3.0370","article-title":"Estrogen receptor null mice: what have we learned and where will they lead us?","volume":"20","author":"Couse","year":"1999","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2008.04.009_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1028-4559(09)60248-5","article-title":"Expression of estrogen receptors alpha and beta mRNA and alkaline phosphatase in the differentiation of osteoblasts from elderly postmenopausal women: comparison with osteoblasts from osteosarcoma cell lines","volume":"45","author":"Chen","year":"2006","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2008.04.009_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bone.2006.11.001","article-title":"Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass","volume":"40","author":"Recker","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2008.04.009_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women","volume":"288","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.maturitas.2008.04.009_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14596-5","article-title":"Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2008.04.009_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer","volume":"354","author":"Yager","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib9","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen receptor modulators\u2014mechanism of actions and application to clinical practice","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/jnci\/djk062","article-title":"SERMs: meeting the promise of multifunctional medicines","volume":"99","author":"Jordan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2008.04.009_bib11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrc2048","article-title":"Chemoprevention of breast cancer with selective estrogen-receptor modulators","volume":"7","author":"Jordan","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.maturitas.2008.04.009_bib12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.maturitas.2008.04.009_bib13","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.maturitas.2008.04.009_bib14","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: 4-year results from a randomized clinical trial","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.04.009_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2008.04.009_bib16","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2008.04.009_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib18","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes","volume":"295","author":"Vogel","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.maturitas.2008.04.009_bib19","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1001\/jama.295.23.joc60075","article-title":"Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Land","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.maturitas.2008.04.009_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.maturitas.2008.04.009_bib21","first-page":"1","article-title":"Coronary heart disease in women, randomized clinical trials, HERS and RUTH","volume":"31","author":"Barrett-Connor","year":"1998","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2008.04.009_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.GME.0000058772.59606.2A","article-title":"Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years","volume":"10","author":"Jolly","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.maturitas.2008.04.009_bib23","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S8756-3282(01)00706-2","article-title":"Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women","volume":"30","author":"Neele","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2008.04.009_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jbspin.2006.05.011","article-title":"Comit\u00e9 scientifique du GRIO. How long should patients take medications for postmenopausal osteoporosis?","volume":"74","author":"Briot","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.maturitas.2008.04.009_bib25","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1210\/jc.2002-021855","article-title":"Efficacy and safety of raloxifene 60mg\/day in postmenopausal Asian women","volume":"88","author":"Kung","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.04.009_bib26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","article-title":"Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial","volume":"14","author":"Morii","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2008.04.009_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-007-0462-5","article-title":"Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies","volume":"19","author":"Byrjalsen","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2008.04.009_bib28","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","article-title":"Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis","volume":"162","author":"Maricic","year":"2002","journal-title":"Arch Int Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib29","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1185\/030079905X75032","article-title":"The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and 6 months: a secondary analysis of the MORE trial","volume":"21","author":"Qu","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.maturitas.2008.04.009_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(03)00200-X","article-title":"Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial","volume":"33","author":"Kanis","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2008.04.009_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s001980200125","article-title":"Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation","volume":"13","author":"Siris","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2008.04.009_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","article-title":"Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial","volume":"33","author":"Delmas","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2008.04.009_bib33","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S1701-2163(16)32087-4","article-title":"Canadian Consensus Conference on Osteoporosis, 2006 update","volume":"28","author":"Brown","year":"2006","journal-title":"J Obstet Gynecol Canada"},{"key":"10.1016\/j.maturitas.2008.04.009_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","article-title":"Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density","volume":"17","author":"Riggs","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2008.04.009_bib35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1067\/mob.2002.121896","article-title":"Effects of tibolone and a continuous combined HRT regimen on mammographic breast density","volume":"186","author":"Lundstrom","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jnci\/93.1.51","article-title":"Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo","volume":"93","author":"Freedman","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2008.04.009_bib37","first-page":"961","article-title":"Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind placebo controlled, randomized clinical trial in postmenopausal patients","volume":"10","author":"Dowsett","year":"2001","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.maturitas.2008.04.009_bib38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jama.287.2.216","article-title":"Serum estradiol level and risk of breast cancer during treatment with raloxifene","volume":"287","author":"Cummings","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.maturitas.2008.04.009_bib39","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1200\/JCO.2001.19.12.3111","article-title":"Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the Multiple Outcomes of Raloxifene Evaluation study participants","volume":"19","author":"Lippman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib40","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1359\/JBMR.040406","article-title":"Risk\u2013benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial","volume":"19","author":"Barrett-Connor","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2008.04.009_bib41","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/CEJ.0b013e328011ed2d","article-title":"Hormonal interventions to prevent hormonal cancers: breast and prostate cancers","volume":"16","author":"Dunn","year":"2007","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.maturitas.2008.04.009_bib42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2005.08.028","article-title":"Prevention of hormone-related cancers: breast cancer","volume":"23","author":"Dunn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Int Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib44","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Int Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.04.009_bib46","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-145-10-200611210-00021","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"145","author":"Grey","year":"2006","journal-title":"Ann Int Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-145-10-200611210-00022","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"145","author":"Watts","year":"2006","journal-title":"Ann Int Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.maturitas.2008.04.009_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00774-006-0735-7","article-title":"Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women","volume":"25","author":"Pasion","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.maturitas.2008.04.009_bib50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalska","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.04.009_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1028-4559(07)60001-1","article-title":"Reconsideration of tamoxifen use for breast cancer","volume":"46","author":"Wang","year":"2007","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1028-4559(08)60118-7","article-title":"Secretory endometrial adenocarcinoma in a tamoxifen user with breast cancer after menopause","volume":"46","author":"Wu","year":"2007","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib53","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1028-4559(08)60051-0","article-title":"The role of selective estrogen receptor modulator on breast cancer\u2014from tamoxifen to raloxifene","volume":"47","author":"Lee","year":"2008","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2008.04.009_bib54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11154-007-9034-4","article-title":"SERMs for the treatment and prevention of breast cancer","volume":"8","author":"Swaby","year":"2007","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.maturitas.2008.04.009_bib55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jnci\/djj253","article-title":"Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs","volume":"98","author":"Vastag","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.maturitas.2008.04.009_bib56","first-page":"817","article-title":"Effects of oral contraceptives on fibrinolytic system among Japanese and American women","volume":"38","author":"Ogino","year":"1986","journal-title":"[Article in Japanese] Nippon Sanka Fujinka Gakkai Zasshi"},{"key":"10.1016\/j.maturitas.2008.04.009_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/intqhc\/mzi070","article-title":"Patient ethnicity and use of venous thromboembolism prophylaxis","volume":"18","author":"Gelber","year":"2006","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.maturitas.2008.04.009_bib58","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.amjmed.2003.11.020","article-title":"Pulmonary thromboembolism in Asians\/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census","volume":"116","author":"Stein","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.amjmed.2004.01.005","article-title":"What protects Asians from venous thromboembolism?","volume":"116","author":"Klatsky","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib60","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1210\/jc.2005-2827","article-title":"Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer","volume":"91","author":"Eng-Wong","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2008.04.009_bib61","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003495-200666020-00005","article-title":"Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women","volume":"66","author":"Vogelvang","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.maturitas.2008.04.009_bib62","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00774-006-0689-9","article-title":"Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women","volume":"24","author":"Komi","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.maturitas.2008.04.009_bib63","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1345\/aph.1H428","article-title":"Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis","volume":"41","author":"Stump","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.maturitas.2008.04.009_bib64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/OGX.0b013e31816400d7","article-title":"Selective estrogen receptor modulators: an update on recent clinical findings","volume":"63","author":"Shelly","year":"2008","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.maturitas.2008.04.009_bib65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00002512-200724050-00002","article-title":"Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development","volume":"24","author":"Gennari","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.maturitas.2008.04.009_bib66","first-page":"93","article-title":"Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses","volume":"52","author":"Carranza-Lira","year":"2007","journal-title":"Int J Fertil Womens Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib67","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH07-07-0468","article-title":"Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis","volume":"99","author":"Adomaityte","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.maturitas.2008.04.009_bib68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ahj.2003.12.019","article-title":"Cardiovascular effects of raloxifene: the arterial and venous systems","volume":"147","author":"Blumenthal","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.maturitas.2008.04.009_bib69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2362.2007.01905.x","article-title":"Role of raloxifene on platelet metabolism and plasma lipids","volume":"38","author":"Nanetti","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.maturitas.2008.04.009_bib70","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over 8 years in a clinical trial setting","volume":"21","author":"Martino","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.maturitas.2008.04.009_bib71","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1056\/NEJMe068120","article-title":"Risk\u2013benefit profiles of raloxifene for women","volume":"355","author":"Stefanick","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2008.04.009_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.maturitas.2007.02.001","article-title":"Postmenopausal hormone therapy: the way ahead","volume":"57","author":"Pines","year":"2007","journal-title":"Maturitas"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512208001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512208001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:45:06Z","timestamp":1759913106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512208001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0378512208001163"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2008.04.009","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2008.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}